Core Insights - HeartSciences Inc. has partnered with the University of the West of England to establish a Reference Center for ECG Education and Technology, utilizing its MyoVista Insights™ platform and MyoVista® wavECG™ device as exclusive ECG technologies [1][2][3] Group 1: Partnership and Technology Adoption - The MyoVista Insights and MyoVista wavECG device will be exclusively used in UWE's cardiac and physiological science teaching programs, aimed at training future cardiac scientists [2] - This partnership supports NHS England workforce priorities and enhances the UK's cardiac diagnostic capacity [2][3] Group 2: Educational Impact - The establishment of the UWE ECG Education and Technology Reference Center will serve as a nationally aligned academic reference site, facilitating clinical adoption discussions with NHS trusts and providing real-world validation of MyoVista Insights™ [3] - The MyoVista Insights platform is noted for advancing ECG analysis beyond traditional methods, enhancing student engagement and understanding of cardiac electrophysiology [4] Group 3: Strategic Positioning - The collaboration reinforces HeartSciences' long-term commercial positioning within the UK healthcare ecosystem, creating a strategically important reference site for broader engagement with the NHS [3][4] - The CEO of HeartSciences expressed satisfaction with the partnership, highlighting its significance for clinical and educational value [4]

Core Viewpoint - HeartSciences Inc. has partnered with Cibolo Rural Health Networks to provide its MyoVista Insights™ ECG management platform to a network of 123 independent hospitals, enhancing ECG workflow efficiency and clinical decision-making [1][2][4]. Group 1: Company Overview - HeartSciences is a healthcare information technology company focused on advancing electrocardiography through artificial intelligence integration [1][5]. - The MyoVista Insights platform is a cloud-native ECG management system designed to improve clinical efficiency and decision-making [5]. Group 2: Partnership Details - Cibolo Health has selected MyoVista Insights as its endorsed ECG management platform for its network of independent hospitals across six states [2][4]. - The collaboration aims to modernize legacy ECG workflows, allowing physicians to interpret ECGs more quickly and efficiently [2][4]. Group 3: Technology and Benefits - MyoVista Insights provides secure, cloud-based ECG data management across various devices and file formats, supporting the integration of AI-ECG algorithms into clinical practice [3]. - The partnership aligns with Cibolo Health's mission to enhance care quality and operational efficiency while managing costs for its member hospitals [4][6].

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended October 31, 2025, with a focus on operational performance and business updates[7]. - The press release detailing the financial results is included as Exhibit 99.1 in the Current Report[9]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[6].

Core Viewpoint - HeartSciences Inc. is advancing its MyoVista Insights™ healthcare IT platform and has submitted its MyoVista® wavECG™ device for FDA clearance, marking significant progress in the commercialization of its ECG technology [1][2][5]. Group 1: Business Developments - The Company has made substantial advancements in the commercialization of its MyoVista Insights™ platform and has submitted the MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance [2][5]. - MyoVista Insights is classified as a Medical Device Data System (MDDS), which allows for a faster and less costly commercial rollout compared to regulated medical devices [7]. - The platform has received strong validation from early adopters and is currently in commercial discussions with several healthcare institutions, with expectations to announce key customer wins soon [5][7]. Group 2: Financial Results - HeartSciences reported no meaningful revenue for the fiscal second quarter ended October 31, 2025, and had approximately $2.0 million in cash and cash equivalents, along with $4.2 million in shareholders' equity [8]. Group 3: Market Opportunity - The MyoVista Insights platform is designed to host third-party AI-ECG algorithms, positioning the Company to capture a multibillion-dollar market opportunity while reducing costs and time for algorithm development and regulatory clearance [7]. - The Company plans to host an investor call early in the new year to demonstrate the MyoVista Insights software and discuss its commercialization strategy and market opportunity [7].

Financial Position - HeartSciences reported stockholders' equity of $1,786,689 as of January 31, 2025, which is below the Nasdaq minimum requirement of $2.5 million[177]. - As of the date of the report, the Company has received approximately $1.9 million in net proceeds from the Streeterville Note[182]. - Cash and cash equivalents increased to approximately $2.0 million as of October 31, 2025, up from $1.1 million as of April 30, 2025[208]. - The company expects existing cash to be insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern[203]. Revenue and Expenses - HeartSciences expects to generate revenues from installation fees, SaaS usage fees, and fees associated with AI-ECG algorithms through the MyoVista Insights platform[172]. - Revenue for the three and six months ended October 31, 2025, was $2,000 and $4,000, respectively, compared to no revenue for the same periods in 2024[196]. - Research and development expenses decreased by $473,000, or 39%, for the three months and $700,000, or 29%, for the six months ended October 31, 2025, compared to the same periods in 2024[197]. - Selling, general, and administrative expenses increased by $562,000, or 71%, for the three months and $589,000, or 36%, for the six months ended October 31, 2025, compared to the same periods in 2024[198]. - Interest expense rose to $280,000 and $463,000 for the three and six months ended October 31, 2025, representing increases of 137% and 231%, respectively, compared to the same periods in 2024[199]. - The company incurred a net loss of $4.4 million for the six months ended October 31, 2025, with an accumulated deficit of $80.5 million[202]. - Net cash used in operating activities was $4.3 million for the six months ended October 31, 2025, primarily due to the net loss[211]. - Net cash provided by financing activities was $5.2 million during the six months ended October 31, 2025, primarily from the issuance of Series D Preferred Stock and warrants[212]. Funding and Stock Issuance - The Company has issued 1,912,383 Units consisting of Series D Preferred Stock and Warrants for gross proceeds of approximately $6.7 million[186]. - The Series D Preferred Stock Offering has a maximum offering amount of $15.0 million, with each Unit priced at $3.50[183]. - The company issued 1,912,383 Units for gross proceeds of approximately $6.7 million during the six months ended October 31, 2025[204]. Regulatory and Product Development - The MyoVista wavECG device was submitted to the FDA for 510(k) premarket clearance in December 2025[175]. - The Company received a "Breakthrough Device" designation from the FDA for its aortic stenosis ECG algorithm in June 2025[181]. - The Company plans to separate FDA submissions for the MyoVista wavECG device and the impaired cardiac relaxation AI-ECG algorithm due to updated clinical standards[173]. Operational Challenges - HeartSciences has experienced recurring losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern[176].

Core Insights - HeartSciences Inc. has submitted its MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance, marking a significant regulatory milestone in its commercialization strategy [1][2] Company Overview - HeartSciences is a healthcare information technology company focused on enhancing ECG/EKG usage through artificial intelligence integration [3] - The MyoVista Insights platform is a next-generation ECG management system designed to improve clinical efficiency and decision-making [3] Product Details - The MyoVista wavECG device offers conventional ECG functionality and is capable of hosting AI-ECG algorithms [2] - The company has opted to separate the FDA submissions for the MyoVista wavECG device and its AI-ECG software algorithm to align with updated clinical standards and expedite the regulatory review process [2] Strategic Developments - The separation of submissions is intended to simplify the regulatory pathway and accelerate device clearance while allowing for future deployment of the AI-ECG algorithm across multiple platforms [2] - The company is making progress with its MyoVista Insights platform and is engaged in commercial discussions with healthcare institutions, expecting to announce initial customer deployments soon [2]

Core Insights - HeartSciences Inc. has announced the commercial release of MyoVista Insights™ version 1.1, enhancing usability and clinical interpretation capabilities of ECG systems [1][2] - The platform is designed to improve workflow efficiency and expand interoperability across various ECG devices, making it a vendor and device agnostic solution [2][3] Product Features - MyoVista Insights is a cloud-native ECG management system that integrates AI ECG algorithm models from multiple partners, streamlining data management and improving workflow efficiency [2] - The updated version 1.1 provides a more intuitive platform for cardiac care, allowing clinicians to quickly interpret complex ECG data and make informed decisions [3] Market Position - Since its launch in May 2025, MyoVista Insights has received strong validation from early adopters and is currently in commercial discussions with several leading healthcare institutions [2] - The company aims to announce key customer deployments in the near term, indicating a positive market reception and potential growth opportunities [2]

Core Viewpoint - HeartSciences Inc. (HSCS) has shown a downtrend recently, with an 8.3% loss over the past two weeks, but a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, suggesting that selling pressure may be subsiding [2][5]. - This pattern forms when a stock opens lower, makes a new low, but then closes near or above the opening price, indicating that bulls may be gaining control [4][5]. - Hammer candles can appear on various timeframes and are utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is a strong consensus among Wall Street analysts to raise earnings estimates for HSCS, which supports the bullish case for the stock [2][7]. - The consensus EPS estimate for the current year has increased by 57.4% over the last 30 days, indicating analysts' agreement on the company's improved earnings potential [8]. - HSCS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Financial Performance - HeartSciences Inc. reported financial results for the quarter ended July 31, 2025, with a focus on operational performance and business updates[7]. - The report does not include specific financial metrics or performance indicators, as the detailed results are provided in the press release[8]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[6]. Stock Information - A press release detailing the financial and operational results was issued on September 11, 2025[7]. - The company's common stock and warrants are traded on The Nasdaq Stock Market LLC under the symbols HSCS and HSCSW, respectively[5].

Core Insights - HeartSciences Inc. reported significant advancements in the first quarter of fiscal 2026, including the FDA Breakthrough Device Designation and the launch of MyoVista Insights, an AI-powered ECG management platform [2][5][8] Financial Performance - For FQ1 2026, HeartSciences reported no meaningful revenue, with approximately $2.8 million in cash and cash equivalents and $3.1 million in shareholders' equity as of July 31, 2025 [9][10] - The company raised an additional $0.8 million through a Reg A+ offering and converted $0.7 million of debt into equity, enhancing its financial position [9] Product Development - MyoVista Insights is a cloud-native software platform aimed at modernizing ECG management systems and facilitating access to AI-ECG algorithms without the need for new ECG devices [6][11] - The platform is designed to integrate with existing ECG hardware and clinical workflows, with CPT reimbursement codes approved by CMS to support AI-ECG adoption [6] - The MyoVista wavECG device is set to host AI-ECG algorithms and is on track for FDA 510(k) submission within the current calendar year [6] Regulatory and Market Position - The FDA granted Breakthrough Device designation for HeartSciences' aortic stenosis ECG algorithm, validating the company's AI-ECG opportunity [5][8] - The company plans to update its algorithms in response to new guidelines from the American Society of Echocardiography, which may enhance its commercial value [6] Intellectual Property - HeartSciences expanded its intellectual property portfolio, holding 44 granted patents worldwide, including a key U.S. patent for estimating echocardiographic parameters via ECG [7]